健康新聞
All coverage
- Nyheder om Alitretinoin
- Nyheder om Allopurinol
- Nyheder om Anakinra
- Nyheder om Atezolizumab
- Nyheder om Atosiban
- Nyheder om Avapritinib
- Nyheder om Avelumab
- Nyheder om Axitinib
- Nyheder om Becaplermin
- Nyheder om Bevacizumab
- Nyheder om Bezlotoxumab
- Nyheder om Bimatoprost
- Nyheder om Brodalumab
- Nyheder om Cabazitaxel
- Nyheder om Cabozantinib
- Nyheder om Caplacizumab
- Nyheder om Carboplatin
- Nyheder om Celecoxib
- Nyheder om Cemiplimab
- Nyheder om Cerliponase alfa
- Nyheder om Cetuximab
- Nyheder om Conestat alfa
- Nyheder om Daptomycin
- Nyheder om Dasatinib
- Nyheder om Desogestrel
- Nyheder om Dexibuprofen
- Nyheder om Diazepam
- Nyheder om Dienogest
- Nyheder om Docetaxel
- Nyheder om Durvalumab
- Nyheder om Eculizumab
- Nyheder om Enrofloxacin
- Nyheder om Etodolac
- Nyheder om Everolimus
- Nyheder om Filgrastim
- Nyheder om Flurbiprofen
- Nyheder om Gemfibrozil
- Nyheder om Guselkumab
- Nyheder om Idelalisib
- Nyheder om Imiquimod
- Nyheder om Inclisiran
- Nyheder om Inotersen
- Nyheder om Isocarboxazid
- Nyheder om Lornoxicam
- Nyheder om Mannitol
- Nyheder om Melphalan
- Nyheder om Meropenem
- Nyheder om Methoxsalen
- Nyheder om Miglustat
- Nyheder om Minoxidil
- Nyheder om Nepafenac
- Nyheder om Nystatin
- Nyheder om Omalizumab
- Nyheder om Paclitaxel
- Nyheder om Palivizumab
- Nyheder om Pemetrexed
- Nyheder om Pertuzumab
- Nyheder om Phenobarbital
- Nyheder om Prasugrel
- Nyheder om Ramucirumab
- Nyheder om Ravulizumab
- Nyheder om Sebelipase alfa
- Nyheder om Sirolimus
- Nyheder om Sonidegib
- Nyheder om Streptozocin
- Nyheder om Sunitinib
- Nyheder om Tagraxofusp
- Nyheder om Tamoxifen
- Nyheder om Tasonermin
- Nyheder om Telmisartan
- Nyheder om Temoporfin
- Nyheder om Thyrotropin alfa
- Nyheder om Tobramycin
- Nyheder om Tolvaptan
- Nyheder om Travoprost
- Nyheder om Vandetanib
- Nyheder om Vismodegib
- Nyheder om Vonicog Alfa
About the Developer
This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).
DkTxGNN is the Denmark site of the company’s “TxGNN Drug Repurposing” product line.
The same system is deployed across 30 countries and regions, each named {CC}TxGNN
(JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care.
Product overview: https://www.yao.care/medical/txgnn/.
The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)